Description

Plagril А (clopidogrel) coated tablets 75 mg. №30

Ingredients

Active ingredient: Clopidogrel bisulfate 75 mg.
Other ingredients: Microcrystalline cellulose, lactose monohydrate, colloidal anhydrous silica, maize starch, hydroxypropylcellulose, hydrogenated castor oil, hypromellose, titanium dioxide (E171).

Dosage

Recommended dosage: 75 mg once daily, with or without food.
Do not exceed the recommended dose unless directed by a healthcare professional.

Indications

Plagril А (clopidogrel) coated tablets are indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Contraindications

Do not use Plagril А (clopidogrel) coated tablets if you have an active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Consult a healthcare provider before use.

Directions

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.

Scientific Evidence

Clopidogrel, the active ingredient in Plagril А, is a platelet aggregation inhibitor that works by irreversibly binding to the P2Y12 ADP receptor on platelets. This action prevents platelet activation and aggregation, reducing the risk of thrombotic events. Several studies have demonstrated the efficacy of clopidogrel in reducing cardiovascular events in high-risk patients.

Additional Information

It is important to inform your healthcare provider about all medications, supplements, and medical conditions before starting Plagril А. Common side effects may include bruising, bleeding, and gastrointestinal upset. If you experience any unusual bleeding or bruising, contact your doctor immediately.

Clopidogrel has been extensively studied in various clinical trials, including the CAPRIE study, which compared clopidogrel to aspirin in patients with atherosclerotic vascular disease. The study showed that clopidogrel was more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction, or vascular death.

Furthermore, the PLATO trial compared clopidogrel to another antiplatelet agent, ticagrelor, in patients with acute coronary syndromes. The study found that ticagrelor was superior to clopidogrel in reducing cardiovascular events, but clopidogrel still demonstrated significant efficacy in this high-risk population.